Trial Profile

A phase 1b/2 clinical trial of LP-184 in combination with the immune checkpoint inhibitor therapies, nivolumab and ipilimumab in patients with advanced non small cell lung cancer patients with KEAP1 and/or STK11 mutations and low expression of PD-L1

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 16 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 May 2025 New trial record
12 May 2025 According to Lantern Pharma media release, Lantern Pharma expects to prepare an application for a Fast Track or Accelerated Approval Designation for this patient population based on data from the planned trial and ongoing analysis from existing models.
12 May 2025 According to Lantern Pharma media release, Misty Dawn Shields is the lead investigator of the trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com